Authors: Caitlin J. McCabe, Sue J. Goldie, David N. Fisman
DOI: 10.1371/journal.pone.0010154
Abstract Summary
Directly observed antiretroviral therapy (DOT) during pregnancy could dramatically reduce mother-to-child HIV transmission at low cost. Mathematical modeling of one million HIV-infected pregnant women showed DOT reduced transmission risk by 61% compared to self-administered treatment, at just $14,233 per quality-adjusted life year gained—making it highly cost-effective and even cost-saving for high-risk patients with elevated viral loads.
Why Brain? 🧠
Directly observed antiretroviral therapy in HIV-positive pregnant women significantly reduces mother-to-child transmission at low cost, potentially saving money when targeted to high-risk cases.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
